Thermo Fisher Scientific Inc. received 510(k) clearance for its EXENT Analyzer and GAM Assay, for faster diagnosis of multiple myeloma. The EXENT System can detect and classify M-proteins, even at low concentrations, providing reliable results. With U.S. clearance and clinical validation, the system is available for clinical use in the U.S. and several international markets. Thermo Fisher Scientific stock was at $586.81, up 0.06% in pre-market trading.

Read more at Nasdaq: Thermo Fisher Gains 510(k) Clearance For EXENT System To Aid Multiple Myeloma Diagnosis